Online Shop
Abacavir
Aceclofenac
Acyclovir
Adefovir
Alfuzosin
Amiloride
Amlodipine
Amoxycillin
Anastrozole
Atropine
Azathioprine
Azithromycin
Baclofen
Bencyclane
Bicalutamide
Bisacodyl
Bisoprolol
Bosentas
Brimonidine
Butenafine
Calcitriol
Capecitabine
Cefixime
Cefoperazone
Cefotetan
Clindamycin
Clobetasone
Clonidine
Cyclosporine
Cyclosporine
Dacarbazine
Desonide
Dextroamphetamine
Didanosine
Duloxetine
Dutasteride
Efavirenz
Emtricitabine
Estradiol
Etoricoxib
Felodipine
Fenofibrate
Finasteride
Flucloxacillin
Fluvoxamine
Formoterol
Formoterol-Budesonide
Gliclazide
Goserelin
Hepatitis
Hyaluronate
Hydrocortisone
Hydroxyurea
Hypromellose
Indinavir
Insulin
Irinotecan
Isotretinoin
Itopride
Ketoconazole
Lamivudine
Levosalbutamol
Linezolid
Lisinopril
Lopinavir
Mercaptopurine
Mesalazine
Mometasone
Mycophenolate
Nateglinide
Nebivolol
Nelfinavir
Nevirapine
Nitrendipine
Olmesartan
Ondansetron
Ormeloxifene
Ornidazole
Orphenadrine
Oseltamivir
Oxcarbazepine
Oxybutynin
Oxytetracycline
Paracetamol
Paracetamol
Piroxicam
Progestin
Propranolol
Pyrantel
Quetiapine
Rabeprazole
Ranolazine
Risedronate
Rizatriptan
Rosiglitazone
Salbutamol
Saquinavir
Sildenafil
Sorbitol
Sucralfate
Tamsulosin
Telmisartan
Tenofovir
Tobramycin
Torsemide
Venlafaxine
Voriconazole
Warfarin
Zolmitriptan

Rabeprazole.

Structure

Rabeprazole - 10 tablets:
- 10 mg - Rabeprazole;

Rabeprazole - 20 tablets:
- 20 mg - Rabeprazole;

Without a Prescription

Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome
Rabeprazole is prescribed for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome.

Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Rabeprazole in combination with amoxicillin and clarithromycin as a three drug regimen, is prescribed for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence.
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted.

Healing of Duodenal Ulcers
Rabeprazole is prescribed for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.

Treatment of Symptomatic GERD
Rabeprazole is prescribed for the treatment of daytime and nighttime heartburn and other symptoms associated with GERD in adults and adolescents 12 years of age and above.

Maintenance of Healing of Erosive or Ulcerative GERD
Rabeprazole is prescribed for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD Maintenance). Controlled studies do not extend beyond 12 months.

Healing of Erosive or Ulcerative GERD
Rabeprazole is prescribed for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered.

Dosage

Rabeprazole tablets should be swallowed whole. The tablets should not be chewed, crushed, or split.

Hepatic Impairment
No dosage adjustment is necessary in patients with mild to moderate hepatic impairment. Administration of Rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to lack of clinical data on Rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.

Renal Impairment
No dosage adjustment is necessary in patients with renal disease elderly patients, in patients with renal disease or in patients with mild to moderate hepatic impairment. Administration of Rabeprazole to patients with mild to moderate liver impairment resulted in increased exposure and decreased elimination. Due to the lack of clinical data on Rabeprazole in patients with severe hepatic impairment, caution should be exercised in those patients.

Short-term Treatment of GERD in Adolescent Patients 12 Years of Age and Above
The recommended oral dose for adolescents 12 years of age and above is 20 mg once daily for up to 8 weeks.

Treatment of Pathological Hypersecretory Conditions Including Zollinger-Ellison Syndrome
The dosage of Rabeprazole in patients with pathologic hypersecretory conditions varies with the individual patient. The recommended adult oral starting dose is 60 mg once a day. Doses should be adjusted to individual patient needs and should continue for as long as clinically prescribed. Some patients may require divided doses. Doses up to 100 mg QD and 60 mg BID have been administered. Some patients with Zollinger-Ellison syndrome have been treated continuously with Rabeprazole for up to one year.

Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence
Clarithromycin 500 mg Twice daily for 7 days
Amoxicillin 1000 mg Twice daily for 7 days
Rabeprazole 20 mg Twice daily for 7 days
All three medications should be taken twice daily with the morning and evening meals.
It is important that patients comply with the full 7-day regimen.

Healing of Duodenal Ulcers
The recommended adult oral dose is one Rabeprazole 20 mg delayed-release tablet to be taken once daily after the morning meal for a period up to four weeks. Most patients with duodenal ulcer heal within four weeks. A few patients may require additional therapy to achieve healing.

Treatment of Symptomatic GERD
The recommended adult oral dose is one Rabeprazole 20 mg delayed-release tablet to be taken once daily for 4 weeks. If symptoms do not resolve completely after 4 weeks, an additional course of treatment may be considered.

Maintenance of Healing of Erosive or Ulcerative GERD
The recommended adult oral dose is one Rabeprazole 20 mg delayed-release tablet to be taken once daily.

Healing of Erosive or Ulcerative GERD
The recommended adult oral dose is one Rabeprazole 20 mg delayed-release tablet to be taken once daily for four to eight weeks. For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of Rabeprazole may be considered.

Contraindications

Rabeprazole is contraindicated in patients with known hypersensitivity to Rabeprazole, substituted benzimidazoles or to any component of the formulation.

Form

Strip pack of tablets;

Prescription drugs without a script
Prescription drugs no script
Prescription drugs no prescription
Prescription drugs without a prescription
RX no RX
RX without RX
2004 - 2017